Serum lipid‐bound sialic acid as a marker in breast cancer

Cancer

Volumn 50, Issue 9, 1982, Pages 1815-1819

  Dnistrian, Ann M ^a   Schwartz, Morton K ^a   Katopodis, Nonda ^b   Fracchia, Alfred A ^c   Stock, C Chester ^b  

^a Laboratory of Biochemistry   (United States)

^b Laboratory of Experimental Anti Tumor Testing ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; SIALIC ACID; TUMOR MARKER;

BREAST; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; DIAGNOSIS; MAJOR CLINICAL STUDY; THERAPY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; LIPIDS; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SIALIC ACIDS; TIME FACTORS;

EID: 0019901037     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19821101)50:9<1815::AID-CNCR2820500927>3.0.CO;2-H     Document Type: Article

References (32)

1. Glycolipidbound sialic acid in serum; Increased levels in mice and humans bearing mammary carcinomas
2. Spectrophotometric assay of total lipid bound sialic acid in blood plasma of cancer patients and asymptomatic healthy individuals (Abstr)
3. Serum or plasma lipid bound sialic acid determinations in malignant diseases
4. Improved method to determine lipid bound sialic acid in plasma or serum
5. Plasma glycoproteins in various disease states including carcinoma
6. Serum sialic acid and CEA concentrations in human breast cancer
7. Development of an improved assay for N‐acetyl neuraminic acid (NANA) using high performance liquid chromatography (Abstr)
8. Quantitative estimation of sialic acid II. A colorimetric resorcinol‐hydrochloric acid method
9. Use of butyl acetate in the determination of sialic acid
10. Glycolipids of tumor cell membrane
11. Polysaccharides in cancer: glycoproteins and glycolipids
12. Determination of serum glycoproteins
13. Serum sialic acid elevations in malignant melanoma patients
14. Serum sialic acid and sialyltransferase as monitors of tumor burden in malignant melanoma patients
15. Glycoproteins and human cancer 1. Circulating levels in cancer serum
16. Sialic acid in cancer patients (Abstr)
17. Significance of protein‐bound neuraminic acid levels in patients with prostatic and bladder carcinoma
18. Protein‐bound carbohydrates in breast cancer: Liquid‐chromatographic analysis for mannose, glactose, fucose and sialic acid in serum
19. Significance of serum fucose, sialic acid, haptoglobine, and phospholipid levels in the evolution and treatment of breast cancer
20. Gangliosides of plasma membranes from normal rat liver and Morris hepatoma
21. Alternations in glycosphingolipids of plasma membranes from Morris hepatoma 5123TC
22. Gangliosides in blood serum of normal rats and Morris hepatoma 5123 tc‐bearing rats
23. Serum sialic acid levels increased in tumor bearing dogs
24. Increased levels of lipid‐bound sialic acid in thymic lymphocytes and plasma from leukemic AKR/J mice
25. Lipid‐associated sialic acid (LASA) elevated in sera of carcinoma patients (Abstr)
26. Alterations of gangliosides in plasma and red cells of humans bearing melanoma tumors
27. Uber ganglioside in herntumeren
28. Gangliosides in human brain tumors
29. Ganglioside pattern and neuraminic acid content of human gastric and colonic carcinoma
30. Lipid composition of human malignant melanoma tumors at various levels of malignant growth
31. Gangliosides in leukemic and nonleukemic human leukocytes